🔴 Summit Therapeutics is trading 5% down today with no confirmed catalyst

Summit Therapeutics is trading 5% down at $16.95 on September 21, 2026, with no company-specific announcement identified to explain the decline.

• Broader U.S. markets were gaining on September 21, 2026.
• The latest company release, dated September 15, reported updated HARMONi trial data presented at WCLC 2026; subsequent coverage remained broadly positive, including UBS’s Buy reiteration.
• The move therefore appears unexplained rather than driven by a confirmed catalyst.